Doxorubicin hydrochloride supplier

Name
Doxorubicin hydrochloride
EINECS 246-818-3
CAS No. 25316-40-9
Article Data13
CAS DataBase
Density
Solubility Soluble in water.
Melting Point 216 °C (dec.)(lit.)
Formula C₂₇H₃₀ClNO₁₁
Boiling Point 810.3 °C at 760 mmHg
Molecular Weight 579.988
Flash Point 443.8 °C
Transport Information
Appearance orange-red crystalline solid
Safety 53-45-36/37/39-22-7/9
Risk Codes 45-22-40-26/27/28
Molecular Structure
Hazard Symbols T,T+
Synonyms 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S,10S)- (9CI);5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-;Adriamycin, hydrochloride (8CI);ADM hydrochloride;ADR;Adriablastina CS;Adriacin;Adriamycin;Adriblastin;Adriblastina;Adriblastina RD;DOX HCl;FI 106;FI 6804;Lipo-Dox;
PSA 206.07000
LogP 1.50360

Synthetic route

: 29742-67-4
14-bromodaunorubicin hydrochloride

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
In water; dimethyl sulfoxide at 80℃; for 2h;	64%

: C61H69N7O18*5.7HCl

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;

: C63H70N8O18*7.5HCl

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;

: C69H76N8O20*6.5HCl

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;

: 23541-50-6
daunomycin hydrochloride

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: 54 percent / bromine / methanol; dioxane; CHCl3 / 144 h / 0 - 5 °C 2: 64 percent / dimethylsulfoxide; H2O / 2 h / 80 °C View Scheme

doxorubicin hydrochloride: doxorubicin hydrochloride

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
Purification / work up;

: doxorubicin

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With 3,6-dimethyl-1,2,4,5-tetrazine In acetonitrile Reagent/catalyst;
With 3,6-dimethyl-1,2,4,5-tetrazine In acetonitrile Reagent/catalyst;

: N-((R)-1-((R)-2-(((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)isonicotinamide

A: N-(pyridin-4-carbonyl)-D-Ala-L-Proline

B: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With fibroblast activating protein In water Kinetics; Reagent/catalyst; Enzymatic reaction;

: C44H42F2N4O14

A: C17H15F2N3O4

B: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With fibroblast activating protein In water Enzymatic reaction;

: C47H55N5O20S2

A: C21H30N4O10S3

B: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
Stage #1: C47H55N5O20S2 With triethyl ammonium acetate; triethylamine In aq. buffer at 20℃; for 2h; pH=9.5 - 9.9; Darkness; Stage #2: With acetic acid In aq. buffer pH=8.2; Darkness; Stage #3: In aq. buffer pH=6-7; Darkness;

: C63H88BNO17S2

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With dihydrogen peroxide for 48h;

: 25316-40-9
doxorubicin hydrochloride

: 23214-92-8
doxorubicin

Conditions

Conditions	Yield
With triethylamine In chloroform at 25℃; for 24h; Darkness;	100%
With 4 Å molecular sieves Aqueous carbonate buffer;	73%
With triethylamine In dimethyl sulfoxide for 1h;

: 120-18-3
naphthalene-2-sulfonate

: 25316-40-9
doxorubicin hydrochloride

: 1246449-86-4
doxorubicin naphthalene-2-sulfonate

Conditions

Conditions	Yield
Stage #1: doxorubicin hydrochloride With potassium tert-butylate In tetrahydrofuran at 20.2 - 21.4℃; for 1.41667h; Inert atmosphere; Stage #2: naphthalene-2-sulfonate In tetrahydrofuran at 20℃; for 1h; Inert atmosphere;	100%

: Fmoc-Phe-Lys(MMT)-PABC-PNP

: 25316-40-9
doxorubicin hydrochloride

: 847871-55-0
Fmoc-Phe-Lys(MMT)-PABC-Dox

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In 1-methyl-pyrrolidin-2-one at 20℃;	99.6%

: 82911-69-1
N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide

: 25316-40-9
doxorubicin hydrochloride

: N-Fmoc doxorubicin

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 24h; Inert atmosphere; Darkness;	99%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;	80%
With N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; for 2h;	80%

: 1451073-54-3
carbonic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester 4-nitro-phenyl ester

: 25316-40-9
doxorubicin hydrochloride

: 1451073-56-5
{3-hydroxy-2-methyl-6-[3,5,12-trihydroxy-3-(2-hydroxy-acetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy]-tetrahydro-pyran-4-yl}-carbamic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester

Conditions

Conditions	Yield
With triethylamine In 1-methyl-pyrrolidin-2-one at 20℃; for 72h;	99%
With triethylamine In 1-methyl-pyrrolidin-2-one at 20℃; for 72h; Darkness;	99%

: 25316-40-9
doxorubicin hydrochloride

: 89889-52-1
biotinamidocaproate N-hydroxysuccinimide ester

: 1401539-59-0
C43H54N4O14S

Conditions

Conditions	Yield
With pyridine; dmap at 20℃; for 16h;	98%

: 25316-40-9
doxorubicin hydrochloride

: 76-05-1
trifluoroacetic acid

: 1071-93-8
adipic acid dihydrazide

: C33H41N5O12*2C2HF3O2

Conditions

Conditions	Yield
In methanol at 20℃; for 5h;	97%

...Expand

: 25316-40-9
doxorubicin hydrochloride

: 104-15-4
toluene-4-sulfonic acid

: doxorubicin tosylate

Conditions

Conditions	Yield
Stage #1: doxorubicin hydrochloride With potassium tert-butylate In tetrahydrofuran at 19 - 22.4℃; for 1.91667h; Inert atmosphere; Stage #2: toluene-4-sulfonic acid In tetrahydrofuran at 20℃; for 0.5h;	97%

: C47H51N7O11S2

: 25316-40-9
doxorubicin hydrochloride

: C68H75N7O19S2

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 16h; Inert atmosphere;	97%

: 64987-85-5
4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid N-succinimidyl ester

: 25316-40-9
doxorubicin hydrochloride

: 400647-59-8
doxorubicin-succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 12h;	96%
With triethylamine In N,N-dimethyl-formamide at 20℃;
With triethylamine In N,N-dimethyl-formamide
With triethylamine In N,N-dimethyl-formamide at 20℃; pH=Ca. 8; Darkness;

: 25316-40-9
doxorubicin hydrochloride

: 80-17-1
benzenesufonyl hydrazide

: 13-benzenesulfonylhydrazone-doxorubicin hydrochloride

Conditions

Conditions	Yield
In methanol at 0 - 45℃; for 16 - 240h;	96%

poly(17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester of 6-(2-methacryloylamino)hexanoic acid-co-N1-(6-hydrazino-6-oxohexyl)-2-methylacrylamide-co-N-(2-hydroxypropyl)methacrylamide): poly(17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester of 6-(2-methacryloylamino)hexanoic acid-co-N1-(6-hydrazino-6-oxohexyl)-2-methylacrylamide-co-N-(2-hydroxypropyl)methacrylamide)

: 25316-40-9
doxorubicin hydrochloride

PHPMA-AH-NH-N=DOX-co-MA-AH-chol: PHPMA-AH-NH-N=DOX-co-MA-AH-chol

Conditions

Conditions	Yield
acetic acid In methanol at 25℃; for 22h;	96%

: C21H20N2O6

: 25316-40-9
doxorubicin hydrochloride

: C42H44N2O14

Conditions

Conditions	Yield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;	96%

: C19H14Cl2N2O6

: 25316-40-9
doxorubicin hydrochloride

: C40H38Cl2N2O14

Conditions

Conditions	Yield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;	95%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;	95%

: 1350891-95-0
(2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl) 4-nitrophenyl carbonate

: 25316-40-9
doxorubicin hydrochloride

: 1350892-00-0
N-(2,3,4-tri-O-acetyl-α-L-rhamnopyranosyloxycarbonyl)doxorubicin

Conditions

Conditions	Yield
With triethylamine In N,N-dimethyl-formamide	94%

: C59H106N2O30

: 25316-40-9
doxorubicin hydrochloride

: C82H130N2O38

Conditions

Conditions	Yield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 14h; Inert atmosphere; Darkness;	94%

: 25316-40-9
doxorubicin hydrochloride

: 407-25-0
trifluoroacetic anhydride

: 26295-56-7
N-Trifluoroacetyladriamycin

Conditions

Conditions	Yield
With pyridine In diethyl ether at -30 - 0℃; for 3h; Schlenk technique;	94%
With pyridine In diethyl ether at -20℃; for 0.5h;	91%

: (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-(((S)-4-amino- 1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1,4-dioxobutan-2-yl)amino)- 1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)carbamate

: 25316-40-9
doxorubicin hydrochloride

: Nα-Fmoc-Ala-Ala-Asn-PABC-doxorubicin

Conditions

Conditions	Yield
With benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide Darkness;	94%

: (E)-2,5-dioxopyrrolidin-1-yl 1-(cyclooct-4-en-1-yloxy)-1-oxo-5,8,11,14-tetraoxa-2-azaheptadecan-17-oate

: 25316-40-9
doxorubicin hydrochloride

: C47H62N2O18

Conditions

Conditions	Yield
With triethylamine In dimethyl sulfoxide at 20℃; for 24h; Darkness;	94%

: 1039044-92-2
6-azidohexanoic hydrazide

: 25316-40-9
doxorubicin hydrochloride

: C33H40N6O11*ClH

Conditions

Conditions	Yield
With acetic acid; sodium sulfate In methanol at 20℃; for 12h; Darkness;	93%
With acetic acid; sodium sulfate In methanol at 65℃; for 24h; Darkness;	62.4%
With acetic acid; sodium sulfate In methanol at 65℃; for 24h;	62.4%
With acetic acid In methanol

: C27H25N3O14S2

: 25316-40-9
doxorubicin hydrochloride

: C48H49N3O22S2

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 5h;	93%

: 1169394-01-7
linolenyl hydrazide

: 25316-40-9
doxorubicin hydrochloride

: C45H59N3O11*ClH

Conditions

Conditions	Yield
With trifluoroacetic acid In methanol at 20℃;	92%

: 1596412-91-7
C17H15N5O8

: 25316-40-9
doxorubicin hydrochloride

: 1596412-92-8
C38H39N5O16

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;	92%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;

: 3,4-dithiophenoylmaleimide-N-hexanoic acid

: 25316-40-9
doxorubicin hydrochloride

: N-(hexanamide-N-doxorubicin)-3,4-dithiophenoylmaleimide

Conditions

Conditions	Yield
Stage #1: 3,4-dithiophenoylmaleimide-N-hexanoic acid With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 0.05h; Inert atmosphere; Stage #2: doxorubicin hydrochloride In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 6h; Inert atmosphere;	92%

: 25316-40-9
doxorubicin hydrochloride

: 180839-15-0
diprop-2-enyl N-<(4-<<4-nitrophenoxycarbonyloxy>methyl>phenyl)carbamoyl>-L-glutamate

: N-<4-(dipropen-2-yl-L-glutamylcarbonylamino)benzyloxycarbonyl>doxorubicin

Conditions

Conditions	Yield
With triethylamine In N,N-dimethyl-formamide for 3.5h; Ambient temperature;	91.1%

: 25316-40-9
doxorubicin hydrochloride

: N-(9-fluorenylmethoxycarbonyl)-β-alanyl-L-leucyl-L-alanyl-L-leucine

: 274913-06-3
N-[N-(9-fluorenylmethoxycarbonyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]doxorubicin

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 2h;	90%

: 25316-40-9
doxorubicin hydrochloride

: 76-05-1
trifluoroacetic acid

: 4-(4-(N-maleimido)phenyl)butyric acid hydrazide hydrochloride

: C41H42N4O13*C2HF3O2

Conditions

Conditions	Yield
In methanol at 20℃; for 5h;	90%

...Expand

: 6318-55-4
cis-aconitic anhydride

: 25316-40-9
doxorubicin hydrochloride

: 1425615-40-2
cis-aconitic anhydride doxorubicin

Conditions

Conditions	Yield
Stage #1: doxorubicin hydrochloride With sodium hydrogencarbonate In water at 0℃; Stage #2: cis-aconitic anhydride In 1,4-dioxane; water at 0 - 20℃; for 0.666667h; pH=8.5; Stage #3: With hydrogenchloride In 1,4-dioxane; water	90%
With triethylamine In N,N-dimethyl-formamide at 25℃; for 24h;
With triethylamine In N,N-dimethyl-formamide

: 874302-76-8
4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate

: 25316-40-9
doxorubicin hydrochloride

: 1058725-05-5
doxorubicin 2-(pyridy-2-yldithio)ethylcarbamate

Conditions

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 16h; Inert atmosphere;	90%
With triethylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; for 12h; Darkness;	87%
With triethylamine In dichloromethane; N,N-dimethyl-d6-formamide at 20℃; for 12h; Darkness;	87%

: N-(p-benzoic acid)-3,4-dithiophenoylmaleimide

: 25316-40-9
doxorubicin hydrochloride

: N-( p-benzamide-N-doxorubicin)-3,4-dithiophenoylmaleimide

Conditions

Conditions	Yield
Stage #1: N-(p-benzoic acid)-3,4-dithiophenoylmaleimide With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 0.05h; Inert atmosphere; Stage #2: doxorubicin hydrochloride In N,N-dimethyl-formamide at 20℃; under 760.051 Torr; for 6h; Inert atmosphere;	90%

Doxorubicin hydrochloride Consensus Reports

NTP 10th Report on Carcinogens. EPA Genetic Toxicology Program.

Doxorubicin hydrochloride Specification

The Doxorubicin hydrochloride, with the CAS registry number 25316-40-9,is also known as (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride. It belongs to the product categories of Pharmaceuticals;Antitumour. This chemical's molecular formula is C₂₇H₂₉NO₁₁^.HCl and molecular weight is 579.99.Its EINECS number is 246-818-3. What's more,Its systematic name is Adriamycin hydrochloride. It is a Orange-Red Crystalline Solid which is Used as an antineoplastic.Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of daunorubicin.

Physical properties about Doxorubicin hydrochloride are:
(1)ACD/LogP: 2.821; (2)# of Rule of 5 Violations: 3; (3)ACD/LogD (pH 5.5): 0.02; (4)ACD/LogD (pH 7.4): 1.12; (5)ACD/BCF (pH 5.5): 1.00; (6)ACD/BCF (pH 7.4): 1.62; (7)ACD/KOC (pH 5.5): 1.29; (8)ACD/KOC (pH 7.4): 16.07; (9)#H bond acceptors: 12; (10)#H bond donors: 7; (11)#Freely Rotating Bonds: 11; (12)Flash Point: 443.8 °C; (13)Enthalpy of Vaporization: 123.51 kJ/mol; (14)Boiling Point: 810.3 °C at 760 mmHg; (15)Vapour Pressure: 9.64E-28 mmHg at 25°C.

You can still convert the following datas into molecular structure:
(1)SMILES:Cl.O=C2c1c(O)c5c(c(O)c1C(=O)c3cccc(OC)c23)C[C@@](O)(C(=O)CO)C[C@@H]5O[C@@H]4O[C@H]([C@@H](O)[C@@H](N)C4)C;
(2)Std. InChI:InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1;
(3)Std. InChIKey:MWWSFMDVAYGXBV-RUELKSSGSA-N.

Safety Information of Doxorubicin hydrochloride:
The Doxorubicin hydrochloride is harmful if swallowed and very toxic by inhalation, in contact with skin and if swallowed. It may cause cancer. But there is limited evidence of a carcinogenic effect. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) .Avoid exposure - obtain special instructions before use. When you use it ,wear suitable protective clothing, gloves and eye/face protection ,and do not breathe dust. After you use it ,keep container tightly closed, and keep container in a well-ventilated place.

The toxicity data of Doxorubicin hydrochloride are as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	LDLo	intravenous	2571ug/kg/3W- (2.571mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Archives of Internal Medicine. Vol. 137, Pg. 385, 1977.
man	TDLo	intravenous	12mg/kg/26W-I (12mg/kg)	CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA	Annals of Internal Medicine. Vol. 106, Pg. 814, 1987.
mouse	LD50	intramuscular	13700ug/kg (13.7mg/kg)		Drugs in Japan Vol. 6, Pg. 506, 1982.
mouse	LD50	intraperitoneal	11160ug/kg (11.16mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	intravenous	1245ug/kg (1.245mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	oral	698mg/kg (698mg/kg)	SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: MUSCLE WEAKNESS	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
mouse	LD50	subcutaneous	7678ug/kg (7.678mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
rabbit	LD50	intravenous	5980ug/kg (5.98mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: FOOD INTAKE (ANIMAL)	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	intramuscular	16mg/kg (16mg/kg)		Drugs in Japan Vol. 6, Pg. 506, 1982.
rat	LD50	intraperitoneal	16030ug/kg (16.03mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE"	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	intravenous	12510ug/kg (12.51mg/kg)		Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	intravenous	12510ug/kg (12.51mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE"	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	subcutaneous	21840ug/kg (21.84mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE" GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.

Product Name

Doxorubicin hydrochloride

Synthetic route

Doxorubicin hydrochloride Consensus Reports

Doxorubicin hydrochloride Specification

Related Products

Hot Products